Custom peptide analytical method transfer: the receiving-lab brief

A peptide method-transfer brief should define the reportable result, the material being compared and the receiving laboratory’s acceptance criteria. Include the procedure version, reference materials and data-processing rules so that both laboratories assess the same question.

State the purpose of each analytical procedure

A custom peptide project can generate several analytical records before an order reaches routine supply. An identity comparison, an impurity profile and a quantitative content result serve different purposes. The receiving laboratory needs to know which result supports the purchasing decision and which records provide supporting information.

FDA published final ICH Q2(R2) and Q14 guidance in March 2024. Q2(R2) addresses validation; Q14 addresses analytical development and lifecycle knowledge. [1] [2] These are pharmaceutical guidance documents. A research supply project can use their measurement principles to organise a handover without claiming pharmaceutical qualification.

Describe the result in words and units

Replace a brief instruction such as “repeat the HPLC” with a defined task. The task might be to compare a specified impurity profile, confirm the expected identity or measure a named content attribute on a stated basis. Record the units, reporting threshold where relevant and the approved specification version.

If one laboratory reports chromatographic area percentage while the other reports material content, the reports answer different questions. Resolve that mismatch before setting a pass criterion. The separate guide to HPLC purity and peptide content explains the underlying distinction.

Give the receiving laboratory the method knowledge it needs

The handover package should allow the laboratory to identify both the current procedure and the decisions made during development. A single chromatogram leaves out the processing rules, the reference material and the limitations that make the result interpretable.

Choose the transfer approach before testing starts

In its lifecycle section, Q2(R2) describes transfer to a different laboratory in terms of partial or full revalidation and/or comparative analysis of representative samples. It also allows a justified approach where additional transfer experiments are not performed. [1] That provides a useful question for the project owner: what evidence will show that the receiving laboratory can produce the required result?

The answer depends on what changes. A new location using familiar equipment presents a different problem from a new detector, a different reference material or a changed reporting basis. Record those differences in the transfer plan. Do not leave the receiving laboratory to discover them after it has issued a report.

Agree acceptance criteria independently of the first comparison

Set the comparison criteria with the laboratories before reviewing the outcome. Define who can investigate a discrepancy, who approves a justified change and how the final decision enters the purchasing specification. Changing a criterion solely because an initial comparison failed leaves the material decision unsupported.

Plan how the team will handle a discrepancy

A difference between reports can arise from the sample, the procedure or the way a result is expressed. Start with the record trail: material identity, sample history, procedure version, reference qualification and processing rules. Compare equivalent results before attributing the difference to the peptide.

For example, two files may have similar main peaks but use different reporting thresholds for minor components. A purchaser cannot infer equivalent impurity profiles from the images alone. Request the agreed reporting rules and have the responsible analysts explain how the comparison was made.

Close the handover with an approved evidence package

1. Confirm the material, procedure and specification versions used.
2. Record the receiving laboratory’s conclusion against the agreed criteria.
3. Keep supporting data, investigated discrepancies and approved changes with that conclusion.
4. Name the owner of future method changes and repeat-order questions.

Include method-transfer needs in the initial custom peptide synthesis brief. For an existing material, ask analytical project support to define the required comparison and connect it to the quality specification. The project should leave a usable record for the next laboratory and the next order.